Monoclonal Antibody Technology Pioneered a New Era of Biomedicine
Zijin Xia,Yingzhao Wang,Jun Chen
DOI: https://doi.org/10.1360/tb-2020-0511
2020-01-01
Abstract:The advent of monoclonal antibody (mAb) technology has revolutionized many fields of biological and medical researches over the last three decades. The first publication by Miler and Milstein that produced mAbs with predetermined specificity from hybridoma cells was honored as one of the top 10 extraordinary papers marking Nature's 150th anniversary in 2019. Prior to their work, researches relied on polyclonal antibodies (pAbs) that are naturally produced by a mixture of B lymphocytes targeting different epitopes on the antigen. The "mixed" nature of pAbs limits its further applications for diagnosis or clinical therapies due to inconsistency and instability of pAb's quality, specificity and purity between experimental batches. It was until 1975 that Kohler and Milstein first discovered an efficient platform to produce specific monoclonal antibodies from hybridoma cells which are prepared by fusion of specific antibody-producing mouse splenocytes and immortal myeloma cells. The emergence of this technology allows for the generation of specific and homogenous antibodies targeting known antigen under controllable in vitro conditions and making mAbs in large scale. This pioneering work won KOhler and Milstein the Lasker Award and Nobel Prize in Physiology or Medicine in 1984. The discovery of mAb has changed the face of biomedicine and has provided promising future for clinical researches. The technology to produce mAb itself is evolving. Researchers have developed multiple ways to improve antibody efficacy. For example, replacement of mouse mAbs by humanized mAbs solved the problem of immunogenicity and other side effects. Currently, antibody-drug conjugate, bispecific antibodies, nanobodies and other new monoclonal antibodies have made mAbs into a new stage with broader usages. Monoclonal antibodies have unique characteristics including highly homogeneous physical and chemical properties, specificity for binding to antigens, and manageable processing and quality control. Because of these superiorities, monoclonal antibodies are critical tools for scientific research and are extensively used in various fields of biomedicine, especially in biomedical basic research, clinical diagnosis and treatment of immune-related diseases such as malignant tumors, autoimmune diseases, and viral infections. With rapid advances in genetics, cell biology and bioengineering, the application of monoclonal antibody has remarkably expanded from basic science to clinical diagnosis and human therapeutics. Accumulating studies have demonstrated the great value and promise for clinical practices with monoclonal antibodies. It provided novel ideas and methods for the clinical treatment of many refractory diseases, and directly promoted the successful treatment of malignant tumors and autoimmune diseases. In recent years, the immunotherapy using monoclonal antibodies specifically target tumor cells has become one of the most promising cures for cancers. In summary, the mAb technology has promoted the development of basic research in biomedicine, which has laid the foundation for its application in the diagnosis and clinical treatment of various diseases, and provided new insights for the clinical treatment of many refractory diseases. In this review, we will briefly summarize the history of monoclonal antibody development and highlight the broad applications of monoclonal antibody for biomedical researches, clinical diagnosis, and pharmacological uses against malignant tumors, autoimmune diseases, and viral infections.